Mesa Laboratories (NASDAQ:MLAB) Director Sells $800,090.40 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director John James Sullivan sold 7,093 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $112.80, for a total value of $800,090.40. Following the transaction, the director directly owned 17,834 shares of the company’s stock, valued at $2,011,675.20. This represents a 28.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Mesa Laboratories Stock Performance

MLAB opened at $119.72 on Thursday. The firm has a market capitalization of $670.43 million, a P/E ratio of 142.53 and a beta of 0.92. The stock’s 50 day moving average price is $100.85 and its two-hundred day moving average price is $96.75. The company has a quick ratio of 1.32, a current ratio of 1.79 and a debt-to-equity ratio of 0.73. Mesa Laboratories, Inc. has a 12-month low of $58.83 and a 12-month high of $120.45.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 EPS for the quarter. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.The company had revenue of $60.14 million for the quarter.

Mesa Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.5%. The ex-dividend date is Monday, August 31st. Mesa Laboratories’s dividend payout ratio is presently 76.19%.

Hedge Funds Weigh In On Mesa Laboratories

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Boston Partners increased its stake in Mesa Laboratories by 86.6% in the fourth quarter. Boston Partners now owns 213,376 shares of the medical instruments supplier’s stock valued at $16,752,000 after acquiring an additional 99,019 shares during the period. Ranger Investment Management L.P. bought a new position in Mesa Laboratories during the second quarter worth about $17,321,000. Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in Mesa Laboratories during the second quarter valued at approximately $15,507,000. Royce & Associates LP boosted its holdings in Mesa Laboratories by 3.2% during the fourth quarter. Royce & Associates LP now owns 153,352 shares of the medical instruments supplier’s stock valued at $12,038,000 after purchasing an additional 4,794 shares in the last quarter. Finally, Kennedy Capital Management LLC grew its stake in shares of Mesa Laboratories by 19.0% in the 4th quarter. Kennedy Capital Management LLC now owns 144,606 shares of the medical instruments supplier’s stock valued at $11,352,000 after purchasing an additional 23,060 shares during the period. 90.60% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MLAB has been the topic of several research analyst reports. Weiss Ratings upgraded shares of Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Wall Street Zen lowered shares of Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, Wells Fargo & Company increased their target price on shares of Mesa Laboratories from $94.00 to $110.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $110.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.